Trem-cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk AML and Avoids Hematopoietic Toxicity During Gemtuzumab Ozogamicin (GO) Post-Hematopoietic Cell Transplant (HCT) Maintenance